PharmaShots | Incisive News in 3 Shots

Subscribe Now

Triple Negative Breast Cancer

AstraZeneca Signs an Agreement with Daiichi Sankyo to Develop and Commercialize DS-1062 Worth Up to $6B

AstraZeneca Signs an Agreement with Daiichi Sankyo to Develop and Commercialize DS-1062 Worth Up to $6B

July 27, 2020

$OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer$

OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer

May 23, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us